Analysis of comptothecin resistance in yeast: relevance to cancer therapy

Drug Resistance Updates

Volumn 1, Issue 3, 1998, Pages 176-183

  Benedetti, Piero ^a   Benchokroun, Youssef ^c   Houghton, Peter J ^b   Bjornsti, Mary Ann ^c  

^a CNR   (Italy)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001531836     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(98)80037-X     Document Type: Review

References (52)

1. Chen A., and Liu L.F. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34 (1994) 191-218
2. Froelich-Ammon S.J., and Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem 270 (1995) 21429-21432
3. Gupta M., Fujimori A., and Pommier Y. Eukaryotic DNA topoisomerase I. Biochim Biophys Acta 1262 (1995) 1-14
4. Tsao Y.P., Russo A., Nyamuswa G., Silber R., and Liu L.F. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res 53 (1993) 5908-5914
5. Holm C., Covey J.M., Kerrigan D., and Pommier Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese Hamster DC3F cells. Cancer Res 49 (1989) 6365-6368
6. Nelson W.G., and Kasten M.B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14 (1994) 1815-1823
7. Logan T.J., Evans D.L., Mercer E., et al. Expression of a deletion mutant of the E2F1 transcription factor in fibroblasts lengthens S phase and increases sensitivity to S phase-specific toxins. Cancer Res 55 (1995) 2883-2891
8. Slichenmeyer W.J., Nelson W.G., Slebos R.J., and Kastan M.B. Loss of a p53-associated GI checkpoint does not decrease cell survival following DNA damage. Cancer Res 53 (1993) 4164-4168
9. Bjornsti M.-A., Knab A.M., and Benedetti P. Yeast Saccharomyces cerevisiae as a model system to study the cytotoxic activity of the antitumor drug camptothecin. Cancer Chemother Pharmacol 34 (1994) S1-S5
10. Wang J.C. DNA topoisomerases. Annu Rev Biochem 65 (1996) 635-692
11. Castano I.B., Brzoska P.M., Sadoff B.U., et al. Mitotic chromosome condensation in the rDNA requires TRF4 and DNA topoisomerase I in Saccharomyces cerevisiae. Genes Dev 10 (1996) 2564-2576
12. Hsiang Y.-H., Hertzberg R., Hecht S., and Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260 (1985) 14873-14878
13. Porter S.E., and Champoux J.J. The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucl Acids Res 17 (1989) 8521-8532
14. Stewart C.F., Zamboni W.C., Crom W.R., et al. Topoisomerase I interactive drugs in children with cancer. Invest New Drugs 14 (1996) 37-47
15. ten Bokkel Huinink W., Gore M., Carmichael J., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15 (1997) 2183-2193
16. Bronstein I.B., Vorobyev S., Timofeev A., et al. Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies. Oncol Res 8 (1996) 17-25
17. Hann C, Evans DL, Fertala J et al. Increased camptothecin toxicity in mammalian cells expressing Saccharomyces cerevisiae DNA topoisomerase I. J Biol Chem in press.
18. Madden K.R., and Champoux J.J. Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin. Cancer Res 52 (1992) 525-532
19. Beidler D.R., Chang J.-Y., Zhou B.-S., and Cheng Y.-C. Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines. Cancer Res 56 (1996) 345-353
20. Fujimori A., Gupta M., Hoki Y., and Pommier Y. Acquired camptothecin resistance of human breast cancer MCF-7 / C4 cells with normal topoisomerase I and elevated DNA repair. Mol Pharmacol 50 (1996) 1472-1478
21. Weinert T. Yeast checkpoint controls in relevance to cancer. Cancer Surveys 29 (1997) 109-132
22. Donovan S., and Diffley J.F. Replication origins in eukaryotes. Curr Opin Genetics Dev 6 (1996) 203-207
23. Rothstein R. Targeting, disruption, replacement, and allele rescue: integrative DNA transformation in yeast. Methods Enzymol 194 (1991) 281-301
24. Rose M.D., and Broach J.D. Cloning genes by complementation in yeast. Methods Enzymol 194 (1991) 195-230
25. Nitiss J.L., Liu Y.X., and Hsiung Y. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors. Cancer Res 53 (1993) 89-93
26. Knab A.M., Fertala J., and Bjornsti M.-A. Mechanisms of camptothecin resistance in yeast DNA topoisomerase I mutants. J Biol Chem 268 (1993) 22322-22330
27. Kauh E.A., and Bjornsti M.-A. SCTI mutants suppress the camptothecin sensitivity of yeast cells expressing wild-type DNA topoisomerase I. Proc Natl Acad Sci USA 92 (1995) 6299-6303
28. (suppl.). Goffeau A., et al. The yeast genome directory. Nature 387 (1997) 1-105
29. Nitiss J., and Wang J.C. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci USA 85 (1988) 7501-7505
30. Nitiss J., and Wang J.C. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol Pharmacol 50 (1996) 1095-1102
31. Eng W.-K., Faucette L., Johnson R.K., and Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 34 (1988) 755-760
32. Benedetti P., Fiorani P., Capuani L., and Wang J.C. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. Cancer Res 53 (1993) 4343-4348
33. Bjornsti M.-A., Benedetti P., Viglianti G.A., and Wang J.C. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res 49 (1989) 6318-6323
34. Reid R.J.D., Kauh E.A., and Bjornsti M.-A. Camptothecin sensitivity is mediated by the pleiotropic drug resistance network in yeast. J Biol Chem 272 (1997) 12091-12099
35. Knab A.M., Fertala J., and Bjornsti M.-A. A camptothecin-resistant DNA topoisomerase I mutant exhibits altered sensitivities to other DNA topoisomerase poisons. J Biol Chem 270 (1995) 6141-6148
36. Megonigal M.D., Fertala J., and Bjornsti M.-A. Cell cycle arrest and lethality produced by alterations in the catalytic activity of yeast DNA topoisomerase I mutants. J Biol Chem 272 (1997) 12801-12808
37. Jensen A.D., and Svejstrup J.Q. Purification and characterization of human topoisomerase I mutants. Eur J Biochem 236 (1996) 389-394
38. Bjornsti M.-A., and Wang J.C. Expression of yeast DNA topoisomerase I can complement a conditional-lethal DNA topoisomerase I mutation in Escherichia coli. Proc Natl Acad Sci USA 84 (1987) 8971-8975
39. Alsner J., Svestrup J.Q., Kjeldsen E., et al. Identification of an N-terminal domain of eukaryotic DNA topoisomerase I dispensable for catalytic activity but essential for in vivo function. J Biol Chem 267 (1992) 12408-12411
40. Lynn R.M., Bjornsti M.-A., Caron P.R., and Wang J.C. Peptide sequencing and site-directed mutagenesis identify tyrosine-727 as the active site tyrosine of Saccharomyces cerevisiae DNA topoisomerase I. Proc Natl Acad Sci USA 86 (1989) 3559-3563
41. Tanizawa A., Kohn K.W., Kohlhagen G., et al. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry 34 (1995) 7200-7206
42. Lue N., Sharma A., Mondragon A., and Wang J.C. A 26 KDa yeast DNA topoisomerase I fragment - crystallographic structure and mechanistic implications. Structure 3 (1995) 1315-1322
43. Stewart L., Ireton G., and Champoux J. Reconstitution of human topoisomerase I by fragment complementation. J Mol Biol 269 (1997) 355-372
44. Li X.G., Haluska P., Hsiang Y.H., et al. Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis. Biochem Pharmacol 53 (1997) 1019-1027
45. Pommier Y. Eukaryotic DNA topoisomerase I - genome gatekeeper and its intruders, camptothecins. Semin Oncol 23 (1996) 3-10
46. Balzi E., and Goffeau A. Yeast multidrug resistance: the PDR network. J Bioenerg Biomembr 27 (1995) 71-76
47. Mahe Y., Parle-McDermott A., Nourani A., et al. The ATP-binding cassette multidrug transporter Snq2 of Saccharomyces cerevisiae: a novel target for the transcription factors Pdr1 and Pdr3. Mol Micro 20 (1996) 109-117
48. Croop J.M., Tiller G.E., Fletcher J.A., et al. Isolation and characterization of a mammalian homolog of the Drosophila white gene. Gene 185 (1997) 77-85
49. Koike K., Kawabe T., Tanaka T., et al. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 57 (1997) 5475-5479
50. Zamboni W.C., Houghton P.J., Johnson R.K., et al. Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. J Pharmacol Exp Ther 284 (1998) 89-94
51. Wiseman L.R., and Markham A. Irinotecan: a review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 52 (1996) 606-623
52. Wang L.-F., Ting C.-Y., Lo C.-K., et al. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. Cancer Res 57 (1997) 1516-1522